Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) EBIT Margin (2016 - 2025)

Marimed has reported EBIT Margin over the past 15 years, most recently at 10.86% for Q4 2025.

  • Quarterly EBIT Margin fell 710.0% to 10.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.65% through Dec 2025, down 346.0% year-over-year, with the annual reading at 1.76% for FY2025, 342.0% down from the prior year.
  • EBIT Margin was 10.86% for Q4 2025 at Marimed, down from 3.92% in the prior quarter.
  • Over five years, EBIT Margin peaked at 36.85% in Q2 2021 and troughed at 10.86% in Q4 2025.
  • The 5-year median for EBIT Margin is 7.34% (2023), against an average of 9.56%.
  • The largest YoY upside for EBIT Margin was 1507bps in 2021 against a maximum downside of -3561bps in 2021.
  • A 5-year view of EBIT Margin shows it stood at 3.88% in 2021, then surged by 122bps to 8.62% in 2022, then dropped by -28bps to 6.2% in 2023, then tumbled by -161bps to 3.77% in 2024, then plummeted by -188bps to 10.86% in 2025.
  • Per Business Quant, the three most recent readings for MRMD's EBIT Margin are 10.86% (Q4 2025), 3.92% (Q3 2025), and 2.88% (Q2 2025).